Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akero Therapeutics

53.12
+1.512.93%
Volume:877.32K
Turnover:46.22M
Market Cap:4.23B
PE:-14.19
High:53.48
Open:51.55
Low:51.38
Close:51.61
Loading ...

Buy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential

TIPRANKS
·
28 May

Akero Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
27 May

Akero Therapeutics price target raised to $64 from $63 at BofA

TIPRANKS
·
27 May

Akero Therapeutics Inc : Bofa Global Research Raises Price Objective to $64 From $63

THOMSON REUTERS
·
27 May

Patrick Lamy, Senior VP at Akero Therapeutics Inc., Reports Disposal of Common Shares

Reuters
·
24 May

Akero Therapeutics up 16% after Street Insider report on sale being considered

TIPRANKS
·
21 May

Akero Therapeutics exploring potential sale after approach, Street Insider says

TIPRANKS
·
21 May

Chief Development Officer Catriona Yale Reports Disposal of Common Shares in Akero Therapeutics Inc

Reuters
·
20 May

Analysts Are Bullish on Top Healthcare Stocks: Akero Therapeutics (AKRO), BioCardia (BCDA)

TIPRANKS
·
15 May

Akero Therapeutics (AKRO) Receives a Buy from Evercore ISI

TIPRANKS
·
14 May

Andrew Cheng, President and CEO, Reports Disposal of Common Shares in Akero Therapeutics Inc

Reuters
·
14 May

BRIEF-Pfizer Dissolves Share Stake In Akero Therapeutics

Reuters
·
14 May

Pfizer Dissolves Share Stake in Akero Therapeutics- SEC Filing

THOMSON REUTERS
·
14 May

Akero Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
14 May

Akero Therapeutics Advances in MASH Treatment Research

TIPRANKS
·
13 May

Akero Therapeutics price target lowered to $84 from $90 at Morgan Stanley

TIPRANKS
·
13 May

Akero Therapeutics Q1 Net Loss Unchanged

MT Newswires Live
·
12 May

Akero Therapeutics Q1 2025 EPS $(0.90) Beats $(0.99) Estimate, Cash, Cash Equivalents, And Short- And Long-term Marketable Securities As Of March 31, 2025, Were $1.128B, Will Be Sufficient To Fund Its Current Operating Plan Into 2028

Benzinga
·
12 May

Patrick Lamy, Senior VP of Commercial Strategy, Reports Disposal of Akero Therapeutics Inc. Common Shares

Reuters
·
10 May

Akero Therapeutics Reports Positive Trial Data for Prospective Cirrhosis Drug

MT Newswires Live
·
09 May